Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib

Canadian Urological Association Journal

Volumn 8, Issue 11-12, 2014, Pages 398-402

  Richter, Suzanne ^a   Seah, Jo An ^a   Pond, Gregory R ^b   Gan, Hui K ^c   Mackenzie, Mary J ^d   Hotte, Sebastien J ^b   Mukherjee, Som D ^b   Murray, Nevin ^e   Kollmannsberger, Christian ^e   Heng, Daniel ^f   Haider, Masoom A ^a   Halford, Robert ^a   Ivy, S Percy ^g   Moore, Malcolm J ^a   Sridhar, Srikala S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84919918910     PISSN: 19116470     EISSN: 19201214     Source Type: Journal    
DOI: 10.5489/cuaj.2426     Document Type: Article

References (13)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29. http://dx.doi.org/10.3322/caac.21208
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90. http://dx.doi.org/10.1200/JCO.2008.20.1293
3. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31. http://dx.doi.org/10.1056/NEJMoa1303989
4. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase iii trial. Lancet 2008;372:449-56. http://dx.doi.org/10.1016/S0140-6736(08)61039-9
5. Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:760-7. http://dx.doi.org/10.1200/JCO.2013.50.3961
6. Sridhar SS, Mackenzie MJ, Hotte SJ, et al. A phase II study of cediranib (azd 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the pmh phase 2 consortium. Invest New Drugs 2013;31:1008-15. http://dx.doi.org/10.1007/s10637-013-9931-1
7. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (axis): A randomised phase 3 trial. Lancet 2011;378:1931-9. http://dx.doi.org/10.1016/S0140-6736(11)61613-9
8. Porta C, Tortora G, Linassier C, et al. Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: An expert agreement. Med Oncol 2012;29:1896-907. http://dx.doi.org/10.1007/s12032-011-0016-8
9. Procopio G, Sabbatini R, Porta C, et al. Optimizing further treatment choices in short-And long-term responders to first-line therapy for patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 2012;12:1089-96. http://dx.doi.org/10.1586/era.12.76
10. Sabbatini R, Ortega C, Procopio G, et al. Metastatic renal cell carcinoma: How to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. Future Oncol 2013;9:831-43. http://dx.doi.org/10.2217/fon.13.58
11. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356: 2271-81. http://dx.doi.org/10.1056/NEJMoa066838
12. Di Lorenzo G, Buonerba C, Federico P, et al. Third-line sorafenib after sequential therapy with sunitinib and mtor inhibitors in metastatic renal cell carcinoma. Eur Urol 2010;58:906-11. http://dx.doi.org/10.1016/j.eururo.2010.09.008
13. Elfiky AA, Cho DC, McDermott DF, et al. Predictors of response to sequential sunitinib and the impact of prior vegf-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol 2011;29:756-63. http://dx.doi.org/10.1016/j.urolonc.2010.01.008